Chitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells

Simple item page
dc.contributor.authorCanak-Ipek, Tuba
dc.contributor.authorAvci-Adali, Meltem
dc.contributor.authorEkentok Atici, Ceyda
dc.contributor.authorSalva, Emine
dc.contributor.authorOzbas, Suna
dc.date.accessioned2024-08-04T20:10:19Z
dc.date.available2024-08-04T20:10:19Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractClustered regularly interspaced short palindromic repeat (CRISPR)-associated Cas9 nuclease system (CRISPR/Cas9) has emerged as a powerful toolbox for cancer therapy, serving as a gene fixed-point knock-out method. However, suitable gene carrier systems are urgently needed to encapsulate the CRISPR/Cas9 system and to improve the uptake into the cancer cells for anti-cancer therapy. In cancer therapy, breast cancer stem cells should be also targeted besides tumor cells. In this study, we prepared chitosan/CRISPR-Cas9/protamine nanoplexes and performed in vitro characterization. The results showed that the chitosan/protamine complex increased the zeta potential of the VEGF CRISPR/Cas9 plasmid from negative to positive. In vitro cell culture studies showed that VEGF silencing efficiency was 46.19% and 30.2% in MCF-7 and MCF-7s, respectively, after 7 days. The invasion capacity of cancer cells decreased significantly for both cell types. The results indicate that chitosan/VEGF CRISPR/Cas9 plasmid/protamine complexes can be used to reduce VEGF expression, leading to a decrease in the invasion capacity of breast cancer as well as breast cancer stem cells and providing proof of concept for more advanced studies, including in vivo studies, of this system.en_US
dc.description.sponsorshipMarmara University, Department of ScientificResearch Projects [SAG-C-DRP-131216-0531, T?BITAK 2214-A, 1059B141700432]en_US
dc.description.sponsorshipAcknowledgments: Marmara University, Department of ScientificResearch Projects (SAG-C-DRP-131216-0531) . T.CI. was funded by the T?BITAK 2214-A International ResearchFellowship Program for PhD Students (1059B141700432)en_US
dc.identifier.doi10.29228/jrp.292
dc.identifier.endpage96en_US
dc.identifier.issn2630-6344
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85147295633en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage86en_US
dc.identifier.trdizinid1177299en_US
dc.identifier.urihttps://doi.org/10.29228/jrp.292
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1177299
dc.identifier.urihttps://hdl.handle.net/11616/92697
dc.identifier.volume27en_US
dc.identifier.wosWOS:000992608700008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherMarmara Univen_US
dc.relation.ispartofJournal of Research in Pharmacyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectchitosanen_US
dc.subjectprotamineen_US
dc.subjectCRISPR-Cas9en_US
dc.subjectVEGFen_US
dc.subjectbreast canceren_US
dc.subjectbreast cancer stem cellsen_US
dc.titleChitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cellsen_US
dc.typeArticleen_US

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize